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Hereditary breast/ovarian cancer is a well-characterized clinical entity, largely attributed to the inheritance
of BRCA1 or BRCA2 mutations. Among general population, the mutation’s frequency of these genes is very
low; therefore, the identification of two independent mutations in the same family is a rare event. This
study reports the presence of two mutations, one in the BRCA1 and the second in the BRCA2 gene in an
Italian Caucasian kindred. This family is composed of more than 250 individuals, spanning through five
generations, among which endogamy was a common phenomenon. Considering the tumor spectrum, this
family is characterized by a high incidence of different types of cancer. In our study, we considered only
three out of seven family units for BRCA1 and BRCA2 analysis. In one of the family units, we found
independent mutations of both BRCA genes. The BRCA1 mutation on exon 11 (3358T-A) was identified
originally in the index case and subsequently in 18 members of this family, whereas the same mutation was
not detected in a related family member with male breast cancer. The male breast cancer patient led to the
identification, through mutational analysis, of a new BRCA2 mutation (8756delA). This BRCA2 mutation was
also found in the male breast cancer patient’s daughter. The discovery of the BRCA2 mutation allowed us
to alert the patient’s daughter who, otherwise, could be falsely reassured since she had a negative BRCA1
test.
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Introduction
The detection of two independent mutations in both the
breast/ovarian cancer susceptibility genes, BRCA1 and
BRCA2, is rarely described among the members of the
same family. Until now, these mutations were found
together in Ashkenazi Jewish kindred1–6 and in a few cases
of non-Jewish families.7–9 It has to be pointed out that
independent BRCA1 and BRCA2 mutations have never
been detected before in Italian families.
We described an extended Italian family where two
different non-Ashkenazi Jewish mutations, one in the
BRCA1 and the second in the BRCA2 gene, are present in
independent members of this family. The two mutations
described in the present report have never been observed in
the same individual. The genetic testing for BRCA1 and
BRCA2 was performed by direct automated sequencing
(DAS) in 38 members. In this family, we found this BRCA1
mutation in 19 members, six affected and 13 healthy, and a
BRCA2 novel mutation only in a male breast cancer patient
and in his healthy daughter.
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The identification of these independent BRCA1 and
BRCA2 mutations in the same family, represents the first
report in a pedigree not belonging to the Ashkenazi Jewish
population and could reflect the possibility of a ‘de novo’
BRCA2 mutation.
Materials and methods
Family
This five-generation family named M019 (Figure 1),
originating from the north of Italy, was composed of more
than 250 individuals, with a high global incidence of
different types of tumors such as thyroid, lung, brain,
kidney, liver and corpus uteri, as well as nine ovarian, 12
female breast, four stomach and one male breast cancers.
As demonstrated by Ludwig et al,10 BRCA1tr/tr mouse
homozygous mutants, that lose the C-terminal of the
protein, develop different types of tumor, particularly,
carcinomas (breast, lung, liver, uterus) and lymphomas.
Among the family, 38 individuals, six affected and 32
unaffected, were available for BRCA1 and BRCA2 muta-
tional analysis. The spectrum of cancers associated with the
mutation in BRCA1 and BRCA2 genes is shown in Table 1.
BRCA1 and BRCA2 mutational analysis
Blood samples were obtained from members of the family
under informed consent and DNA was extracted using
standard protocols.
For BRCA1 analysis we used 17 pairs of primers, as
described by Friedman et al,11 to amplify exons 2, 3, 5, 6, 8,
11, 13, 16, 17, 18, 19 and 20, the most frequently mutated,
while for BRCA2 analysis, we designed new sets of PCR
primers to study exons 7, 9, 10, 11, 20 and 23. Purification
of PCR products, direct sequencing and subcloning of
fragments with unclear heterozygosity were carried out as
already described.12
Statistical methods
Standardized incidence ratios (SIRs) were calculated by
determining the ratio of the observed patients compared to
the expected number of cases with all the breast and
ovarian cancers. The end point for person-years calculation
was 31 December 2000 or the date of diagnosis of the site-
specific neoplasm under investigation or, the date of death
or emigration when appropriate. The expected number of
subjects with cancer was determined by using 5-year age,
sex and calendar-period specific incidence rates estimated
for the Modena province population.13 As a whole, the
incidence of breast and ovarian cancers was considerably
higher than expected (Table 2).
Results
In all, 38 members of this family were analyzed with DAS
for BRCA1 and BRCA2 mutations. We found the 3358T-A Fi
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BRCA1 nonsense mutation in three patients with breast
cancer, two patients with ovarian cancer and one patient
with uterine adenocarcinoma. Furthermore, 13 healthy
individuals were carriers of the same BRCA1 mutation.
Since the male breast cancer patient was BRCA1 negative
and considering the high incidence of BRCA2 mutations in
families with male breast cancer,14 we performed muta-
tional analysis for the BRCA2 gene on this patient. As a
Table 1 Spectrum of cancers associated with the mutations in BRCA1 and BRCA2 genes
Individual ID BRCA1 3358T-A BRCA2 8756delA Type of cancer Age of onset
1:1 Unknown Unknown None None
1:2 Unknown Unknown None None
2:2 Obligate carrier Unknown Liver 79
2:3 Unknown Unknown Ovary 38
2:4 Obligate carrier Unknown None None
2:5 Obligate carrier Unknown Stomach 90
3:3 Unknown Unknown Kydney 66
3:4 Unknown Unknown Ovary 71
3:5 Yes No Breast 63
3:6 Obligate carrier No Thyroid 78
3:7 Unknown Unknown Stomach 67
3:10 Unknown Unknown None None
3:11 Unknown Unknown Breast 50
3:12 Obligate carrier No Breast 54
3:15 Yes No None None
3:16 Obligate carrier No Ovary 46
3:17 No No None None
3:18 Yes No Ovary 47
3:19 No No None None
3:20 No No None None
3:21 No No None None
3:22 Yes No Ovary 50
3:23 No No None None
3:24 No No None None
3:25 Obligate carrier No Ovary 42
3:26 Unknown Unknown Breast 79
3:27 No Yes Breast 46
3:28 Unknown Unknown Bilateral breast 38,38
3:29 Unknown Unknown None None
4:4 Unknown Unknown Lung 50
4:6 No No None None
4:8 No No None None
4:11 Yes No None None
4:12 Yes No Breast 40
4:17 Unknown Unknown Brain 27
4:20 Yes No Uterine 50
4:21 Yes No Breast 43
4:22 Yes No None None
4:23 No No None None
4:24 No No None None
4:26 Yes No None None
4:27 No No None None
4:29 Yes No None None
4:37 Yes No None None
4:38 Yes No None None
4:43 No No None None
4:44 Yes No None None
4:45 Yes No None None
4:46 Yes No None None
4:47 No Yes None None
4:54 No No None None
5:1 Yes No None None
5:2 Yes No None None
5:3 No No None None
5:4 Yes No None None
5:5 No No None None
5:6 No No None None
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consequence, we detected a BRCA2 mutation on exon 20,
characterized by 8756delA, giving rise to a stop codon
insertion at nucleotide 8815 causing a truncated protein
product. This mutation had never been identified before
and was found also in the patient’s healthy daughter.
Moreover, all the members tested for BRCA1 analysis were
also searched for the 8756delA BRCA2 mutation, but we
did not find any additional carrier.
One BRCA1 female breast cancer patient had an in situ
ductal carcinoma at 43 years of age (4:21 in Figure 1),
whereas two other patients (3:5, 4:12) were characterized
by ductal infiltrating carcinoma with an aggressive pheno-
type: grading III, hormonal receptors negative, high
proliferation rate.12 All the four BRCA1 ovarian cancers
(3:16, 3:18, 3:22 and 3:25) were serous adenocarcinomas,
consistent with the data of other authors.15
The male breast cancer (3:27) was a poorly differentiated,
infiltrating ductal carcinoma. To evaluate the frequency of
this novel deletion in BRCA2 gene, we analyzed 10 other
cases of male breast cancer belonging to unrelated families.
All the cases studied were negative for this mutation.
Furthermore, in our family where the ratio between
ovarian and breast cancers is almost 1:1, the results are in
accordance with the literature data. The relative risk for
breast and ovarian cancer is also similar, being the SIR (see
Table 2) 25.7 for BC and 24.1 for OC. It has to be
considered that the high SIR of the other tumors
(AC¼14.6) could reflect an involvement of 3358T-A
BRCA1 mutation in different types of tumors. The high
cancer risk in this Italian family is therefore consistent with
the studies of Ludwig et al10 and Thompson et al for the
Breast Cancer Linkage Consortium.16
Discussion
In this study, we describe an atypical Italian family
characterized by a large number of individuals and by
endogamy among family members. This family shows two
separate mutations segregating with breast and ovarian
cancer, among multiple siblings. Our family shares many
characteristics with the large kindred of Ashkenazi Jewish,
in which BRCA1 and BRCA2 mutations are frequently
detected. The 3358T-A BRCA1 mutation is certainly
inherited since 50% of the members of the three family
units studied are carriers. Since only the male breast cancer
patient and his daughter were found positive for BRCA2
mutational analysis, the most probable interpretation is
that this is a ‘de novo’ mutation. We cannot exclude the
possibility that the mutation was inherited from the father
or the mother or any maternal relative, since archival
tumor tissue of the parents is not available. Another
possibility is that the male breast case with the BRCA2
mutation might have a different father from the others.
Furthermore, other male breast cancer patients, belonging
to unrelated families, are negative for this specific muta-
tion while they are positive for other recurrent BRCA2
mutations, such as 6174delT and 9326insA. The biopatho-
logical parameters of this BRCA2 cancer show an aggressive
tumor phenotype and this is in contrast with the literature
data characterizing other kinds of mutations.17
This study revealed the importance and the benefit
deriving from the knowledge of an accurate family history
in the context of genetic testing. In fact, the lack of
information about the male breast cancer of individual
3:27, would have made it impossible to identify the second
mutation and, moreover, it would have been misleading
for the patient’s daughter, negative for BRCA1 but resulting
positive for BRCA2. The 3358T-A BRCA1 mutation was
reported, for the first time, by Gayther et al18 in a family
characterized by one ovarian and seven breast cancers. It
was the only mutation, located in the first two-thirds of the
coding sequence, where the breast cancer is higher than
the ovarian cancer incidence. Further studies have shown
that the frequency of ovarian cancer compared to breast
cancer associated with mutations downstream to the
granin motif (nucleotides 3760–3787) was significantly
lower than for other mutations.19 Our data are in
agreement with those of Thompson et al20 that, evaluating
the genotype–phenotype correlations in 356 families with
BrCa1 mutations, demonstrated that the mutations occur-
ring in the regions 2401–4190 are more frequently
involved in the development of ovarian cancer rather than
those mapping at nucleotides 1–2400.
Our findings suggest that the BRCA1 3358T-A mutation
predisposes also to a high incidence of ovarian cancer with
the consequence that the surveillance strategies must be
different and, particularly, we believe appropriate to
consider a prophylactic oophorectomy for the carrier.
Although our data show that there is an elevated cancer
risk for this family, the results do not allow us to draw
conclusions on tumor types other than breast and ovarian
cancer.
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Table 2 Standardized incidence ratio (SIR) of all neo-
plasms, breast cancer and ovarian cancer in the whole
study population
Observed cases Expected cases SIRa 95% CI
ACb 22 1.37 14.6 9.4–22.7
BCc 8 0.23 25.7 11.5–57.1
OCd 6 0.25 24.1 10.8–53.6
aSIR, standardized incidence ratio. bAC, all cancers. cBC, breast cancer.
dOC, ovarian cancer.
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